AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8633674 — intervention group
Group type: COMPARATOR
Intervention: No CUSA (group 2, 20 patients)
Number of subjects: 40
Study 1425524 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 76 mumol (5 mg) Zn/kg diet
Number of subjects: 0
Study 1425524 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 153 mumol (10 mg) Zn/kg diet
Number of subjects: 0
Study 1425524 — intervention group
Group type: COMPARATOR
Intervention: Basal diet alone
Number of subjects: 0
Study 6480851 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy client
Number of subjects: 31
Study 6480851 — intervention group
Group type: COMPARATOR
Intervention: Difficult client
Number of subjects: 31
Study 30900659 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (1.1 g each, 2 pieces daily for 14 days)
Number of subjects: 48
Study 30900659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol chewing gum (1.1 g each, 2 pieces daily for 14 days)
Number of subjects: 48
Study 30900659 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gum)
Number of subjects: 48
Study 29190507 — intervention group
Group type: EXPERIMENTAL
Intervention: M-EI regimen (7 M-courses and 2 EI-courses)
Number of subjects: 409
Study 29190507 — intervention group
Group type: EXPERIMENTAL
Intervention: M-EI regimen
Number of subjects: 409
Study 27421061 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit alcohol approach tendencies
Number of subjects: 0
Study 27421061 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit alcohol avoidance tendencies
Number of subjects: 0
Study 27421061 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit alcohol approach and avoidance tendencies
Number of subjects: 0
Study 25265132 — intervention group
Group type: EXPERIMENTAL
Intervention: OXN PR 20-120mg/day for 12 weeks (non-cancer pain) or 4 weeks (cancer-related pain)
Number of subjects: 75
Study 25265132 — intervention group
Group type: EXPERIMENTAL
Intervention: OXN PR 20-120mg/day
Number of subjects: 75
Study 22518944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle taping (closed basket weave technique)
Number of subjects: 26
Study 22518944 — intervention group
Group type: COMPARATOR
Intervention: No ankle taping (control condition)
Number of subjects: 26
Study 20064275 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy (CIMT)
Number of subjects: 52
Study 20064275 — intervention group
Group type: COMPARATOR
Intervention: Bimanual Training (BIM training)
Number of subjects: 52
Study 20064275 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT
Number of subjects: 52
Study 20064275 — intervention group
Group type: COMPARATOR
Intervention: BIM training
Number of subjects: 52
Study 18691988 — intervention group
Group type: EXPERIMENTAL
Intervention: aranidipine 5 mg
Number of subjects: 30
Study 18691988 — intervention group
Group type: EXPERIMENTAL
Intervention: aranidipine 10 mg
Number of subjects: 30
Study 18691988 — intervention group
Group type: EXPERIMENTAL
Intervention: aranidipine 20 mg
Number of subjects: 30
Study 18691988 — intervention group
Group type: EXPERIMENTAL
Intervention: aranidipine 10 mg (multiple doses)
Number of subjects: 30
Study 18691988 — intervention group
Group type: EXPERIMENTAL
Intervention: M-1 metabolite (aranidipine 10 mg)
Number of subjects: 30
Study 18691988 — intervention group
Group type: EXPERIMENTAL
Intervention: M-1 metabolite (aranidipine 5 mg)
Number of subjects: 30
Study 18691988 — intervention group
Group type: EXPERIMENTAL
Intervention: M-1 metabolite (aranidipine 20 mg)
Number of subjects: 30
Study 18691988 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 15673502 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 0
Study 15673502 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0
Study 15673502 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer treatment strategies
Number of subjects: 0
Study 12422155 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-cm coil catheter
Number of subjects: 26
Study 12422155 — intervention group
Group type: COMPARATOR
Intervention: 5.5-cm coil catheter
Number of subjects: 26
Study 10527297 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention (brief physician- and nurse practitioner-delivered counseling)
Number of subjects: 530
Study 10527297 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 530
Study 7562757 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 10
Study 7562757 — intervention group
Group type: COMPARATOR
Intervention: Global assessments and skin scores
Number of subjects: 10
Study 2189450 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 19
Study 2189450 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 19
Study 772827 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin 50,000 U/kg/d and Kanamycin 10 mg/kg/d
Number of subjects: 51
Study 772827 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 51
Study 31942889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu resistance clones from metagenomic libraries
Number of subjects: 411
Study 31942889 — intervention group
Group type: COMPARATOR
Intervention: Cu-sensitive E. coli strain (ΔCopA)
Number of subjects: 411
Study 31699631 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video on third molar extraction
Number of subjects: 100
Study 28279506 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPYPS scale
Number of subjects: 67
Study 26332338 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii-based Movement Therapy
Number of subjects: 41
Study 26332338 — intervention group
Group type: COMPARATOR
Intervention: modified Constraint-induced Movement Therapy
Number of subjects: 41
Study 23645374 — intervention group
Group type: EXPERIMENTAL
Intervention: PureVision SH lenses with Alcon Opti‐Free Express solution
Number of subjects: 25
Study 23645374 — intervention group
Group type: EXPERIMENTAL
Intervention: PureVision SH lenses with Renu Fresh solution
Number of subjects: 25
Study 23645374 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-lens wearers)
Number of subjects: 25
Study 21590284 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (10, 20, and 40 mg)
Number of subjects: 9
Study 21590284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 19892235 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 5011
Study 19892235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5011
Study 16374781 — intervention group
Group type: EXPERIMENTAL
Intervention: PDL (Pulsed Dye Laser)
Number of subjects: 52
Study 16374781 — intervention group
Group type: EXPERIMENTAL
Intervention: LPDL (Long Pulsed Dye Laser)
Number of subjects: 52
Study 16374781 — intervention group
Group type: COMPARATOR
Intervention: PDL
Number of subjects: 52
Study 16374781 — intervention group
Group type: EXPERIMENTAL
Intervention: LPDL
Number of subjects: 52
Study 15226172 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak probability contrast method
Number of subjects: 0
Study 10642014 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Evaluation and Management (GEM)
Number of subjects: 128
Study 10642014 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 128
Study 9155284 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter valves (seven types available on the UK market in April 1996) tested for 1 week
Number of subjects: 36
Study 9155284 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter valves (same types) tested for ease of opening/closing
Number of subjects: 36
Study 8444070 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (400 mg twice a day)
Number of subjects: 16
Study 8444070 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms four times a day)
Number of subjects: 16
Study 8444070 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50 mg three times a day)
Number of subjects: 16
Study 8444070 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug regimen)
Number of subjects: 16
Study 3707170 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen matrix
Number of subjects: 20
Study 3707170 — intervention group
Group type: COMPARATOR
Intervention: Monsel's solution
Number of subjects: 20
Study 30497420 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodized circuit training
Number of subjects: 60
Study 30497420 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 60
Study 30497420 — intervention group
Group type: COMPARATOR
Intervention: Educational protocol
Number of subjects: 60
Study 27394051 — intervention group
Group type: EXPERIMENTAL
Intervention: In My Shoes (IMS) interview
Number of subjects: 54
Study 27394051 — intervention group
Group type: COMPARATOR
Intervention: Forensic best practice interview
Number of subjects: 54
Study 24127265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 1050
Study 22784474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium stored at room temperature (0.15mg/kg)
Number of subjects: 30
Study 22784474 — intervention group
Group type: COMPARATOR
Intervention: Cisatracurium stored at +4°C (0.15mg/kg)
Number of subjects: 30
Study 21174751 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment combined with hyperbaric oxygen therapy (HBOT) for two weeks
Number of subjects: 120
Study 21174751 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment alone for two weeks
Number of subjects: 120
Study 21174751 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment combined with HBOT
Number of subjects: 120
Study 21174751 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment alone
Number of subjects: 120
Study 19012813 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-bead mixed amphetamine salts (starting dose 12.5 mg)
Number of subjects: 272
Study 19012813 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-bead mixed amphetamine salts
Number of subjects: 272
Study 19012813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 15869337 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirically supported treatments
Number of subjects: 0
Study 15869337 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0
Study 12563460 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 20
Study 12563460 — intervention group
Group type: COMPARATOR
Intervention: Anterior lesser curve seromyotomy with posterior truncal vagotomy (ASPTV)
Number of subjects: 20
Study 12563460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligature of short gastric vessels with PGV or ASPTV
Number of subjects: 20
Study 12563460 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of SpO2 in proximal lesser curve and gastric fundus vs gastric corpus
Number of subjects: 20
Study 10635188 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant supported FPDs (two implants)
Number of subjects: 23
Study 10635188 — intervention group
Group type: COMPARATOR
Intervention: Tooth-implant supported FPDs (one implant and one tooth)
Number of subjects: 23
Study 8942319 — intervention group
Group type: EXPERIMENTAL
Intervention: Questioners rating past behaviors
Number of subjects: 0
Study 8942319 — intervention group
Group type: EXPERIMENTAL
Intervention: Answerers rating past behaviors
Number of subjects: 0
Study 8942319 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction of future performance in a quiz-game setting
Number of subjects: 0
Study 1758244 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1 ml, 0.15 mg) with 3 ml 0.5% hyperbaric bupivacaine
Number of subjects: 40
Study 1758244 — intervention group
Group type: COMPARATOR
Intervention: Saline (3 ml 0.5% hyperbaric bupivacaine plus 1 ml normal saline)
Number of subjects: 40
Study 6215927 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 8
Study 6215927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6215927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 8
Study 30570527 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum maternal ARVs
Number of subjects: 254
Study 30570527 — intervention group
Group type: COMPARATOR
Intervention: Daily infant nevirapine
Number of subjects: 254
Study 28218934 — intervention group
Group type: EXPERIMENTAL
Intervention: Precepting in the Presence of the Patient (PIPP)
Number of subjects: 0
Study 28218934 — intervention group
Group type: COMPARATOR
Intervention: Conference Room Staffing (CRS)
Number of subjects: 0
Study 28218934 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPP
Number of subjects: 0
Study 25661270 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus conventional analgesic treatment
Number of subjects: 60
Study 25661270 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative analgesic treatment
Number of subjects: 60
Study 23399382 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (14 mg for smokers, 7 mg for non-smokers)
Number of subjects: 48
Study 23399382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23399382 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard trials
Number of subjects: 48
Study 23399382 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 48
Study 21739685 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-rehabilitation group
Number of subjects: 90
Study 21739685 — intervention group
Group type: COMPARATOR
Intervention: Body acupuncture group
Number of subjects: 90
Study 21739685 — intervention group
Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 90
Study 19657105 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial sonography (TCS)
Number of subjects: 75
Study 19657105 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy subjects)
Number of subjects: 75
Study 19657105 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger bilateral SN echogenic area
Number of subjects: 75
Study 19657105 — intervention group
Group type: EXPERIMENTAL
Intervention: Small SN echogenic area (SN hypoechogenicity)
Number of subjects: 75
Study 16368659 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported craving scores after exposure to a heroin-related cue
Number of subjects: 76
Study 16368659 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological measures of craving after exposure to a heroin-related cue
Number of subjects: 76
Study 16368659 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective and physiological cue reactivity
Number of subjects: 76
Study 16368659 — intervention group
Group type: EXPERIMENTAL
Intervention: Relation between subjective and physiological cue reactivity
Number of subjects: 76
Study 16368659 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderation effect of social desirability on the relation between subjective and physiological reactivity
Number of subjects: 76
Study 12215608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage patients
Number of subjects: 46
Study 12215608 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 46
Study 11220541 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-of-7 mode-switching algorithm
Number of subjects: 17
Study 11220541 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-of-1 mode-switching algorithm
Number of subjects: 17
Study 11220541 — intervention group
Group type: COMPARATOR
Intervention: standard mode-switching algorithm
Number of subjects: 17
Study 8610716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 micrograms) + albuterol (2.5 mg)
Number of subjects: 195
Study 8610716 — intervention group
Group type: COMPARATOR
Intervention: Placebo + albuterol (2.5 mg)
Number of subjects: 195
Study 1826567 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intradermal recombinant-derived hepatitis B vaccine (1.0 or 1.5 microgram)
Number of subjects: 132
Study 1826567 — intervention group
Group type: COMPARATOR
Intervention: Standard intramuscular dose of hepatitis B vaccine
Number of subjects: 132
Study 7080491 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bemetizide, 20 mg triamterene, 20 mg dihydralazine and 20 mg bupranolol (multiple dose regimen)
Number of subjects: 14
Study 7080491 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bemetizide, 20 mg triamterene, 20 mg dihydralazine and 20 mg bupranolol (single dose regimen)
Number of subjects: 14
Study 30401688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 286
Study 30401688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 30401688 — intervention group
Group type: COMPARATOR
Intervention: Combined (sunitinib plus placebo)
Number of subjects: 286
Study 28120351 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus applied twice daily for 3 weeks
Number of subjects: 50
Study 28120351 — intervention group
Group type: COMPARATOR
Intervention: Topical clotrimazole applied twice daily for 3 weeks
Number of subjects: 50
Study 25282071 — intervention group
Group type: EXPERIMENTAL
Intervention: Exparel (liposomal bupivacaine)
Number of subjects: 80
Study 25282071 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 80
Study 25282071 — intervention group
Group type: EXPERIMENTAL
Intervention: Exparel
Number of subjects: 80
Study 23876536 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 57
Study 23876536 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 57
Study 23876536 — intervention group
Group type: COMPARATOR
Intervention: Both diet and physical exercise
Number of subjects: 57
Study 21804410 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with open reduction and internal fixation using an angular stable plate and cerclages, with physical therapy starting on the third postoperative day.
Number of subjects: 50
Study 21804410 — intervention group
Group type: COMPARATOR
Intervention: Conservative closed treatment including closed reduction if displacement exceeded 50% of the diaphyseal diameter, with physical therapy starting on the fifteenth postoperative day.
Number of subjects: 50
Study 19299806 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-duration continuous femoral nerve block (ropivacaine 0.2%)
Number of subjects: 50
Study 19299806 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 50
Study 18001477 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 2746
Study 18001477 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NAC)
Number of subjects: 2746
Study 15191260 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 9
Study 12215319 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 93
Study 12215319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 9650546 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 200
Study 9650546 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 200
Study 9650546 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 200
Study 9650546 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 650 mg with codeine 60 mg
Number of subjects: 200
Study 9650546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 7648762 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 10
Study 2711990 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 10 mg administered 3 times daily
Number of subjects: 81
Study 2711990 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg administered 3 times daily
Number of subjects: 81
Study 2711990 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg administered 3 times daily
Number of subjects: 81
Study 2711990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 186224 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg twice daily)
Number of subjects: 11
Study 186224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31474339 — intervention group
Group type: EXPERIMENTAL
Intervention: Detomidine gel (40 μg kg‐1) intravaginally (treatment IVG)
Number of subjects: 6
Study 31474339 — intervention group
Group type: COMPARATOR
Intervention: Detomidine hydrochloride (10 μg kg‐1) intravenously (treatment IV)
Number of subjects: 6
Study 28462683 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy plus intensive medical therapy
Number of subjects: 2480
Study 28462683 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stenting plus intensive medical therapy
Number of subjects: 2480
Study 28462683 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy alone
Number of subjects: 2480
Study 25946465 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based curriculum with cell phone reminders (IT)
Number of subjects: 48
Study 25946465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counselling sessions (sLMP)
Number of subjects: 48
Study 25946465 — intervention group
Group type: COMPARATOR
Intervention: Usual care visits (Control)
Number of subjects: 48
Study 23980580 — intervention group
Group type: EXPERIMENTAL
Intervention: BL Group (bupivacaine-lidocaine)
Number of subjects: 93
Study 23980580 — intervention group
Group type: COMPARATOR
Intervention: LIA Group (local infiltration anaesthesia)
Number of subjects: 93
Study 21872138 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (10 mg/d)
Number of subjects: 160
Study 21872138 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol (50 mg/d)
Number of subjects: 160
Study 18996423 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned immunization card and center-based education
Number of subjects: 1500
Study 18996423 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1500
Study 16053592 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-at-home care
Number of subjects: 285